

An aerial photograph of Paris, France, showing the Eiffel Tower in the upper left and the Sacré-Cœur Basilica in the upper right. The city is densely packed with buildings, and the Seine River is visible winding through the center. The lighting suggests a late afternoon or early morning scene.

Intestinal failure and transplantation Necker-Enfants malades, Paris

- **Medical management of intestinal failure**
Florence Lacaille, and the whole team

Where I have been in Turkey

All the places where the tourists go

+ : Taşucu, Bingöl, Trabzon, Edirne, Hopa, Diyarbakir, Konya, Antakya, Harran, Erzurum, Amasya, Cannakale, Adana, Mardin, Nimrut Dag, Gaziantep, Manisa, Tarsus, Iskenderun, Malatya, Kirikkale, Mersin, Gallipoli, Urfa, Karaman ...

Teşekkür ederim

... beni misaafis etiniz için !

And from :

Ibrahim, Oktay, Hasan, Murat : Tx for microvillous atrophy

Mina, Muhammet : microvillous atrophy

Ozan : Tx for tufting enteropathy

Cem : waiting list for Tx, extensive Hirschsprung

What is intestinal insufficiency / failure ?

The gastrointestinal tract is unable to provide enough digestion and absorption capacities for nutritional requirements for growth and development


IF : medico-surgical management

- Gastroenterology-Nutrition
 - parenteral nutrition (PN)
 - prevention of complications
 - home PN
- Surgery
 - neonatal surgery
 - non transplant (reconstructive) surgery
 - intestinal transplantation


Aims of medical management

- Feed the child !
 - growth and development with PN
- Oral > enteral nutrition
- Promotion of intestinal adaptation
- Prevention / treatment of complications
 - infections ; thrombosis ; IFALD ; bone
 - quality of life


Home PN 1980-99, n = 302




Home PN Necker 2000-2010 : n = 251




Consequences of bowel resection



Adaptation : intestinal hypertrophy and villous hyperplasia




Dilatation, muscular hypertrophy, lengthening



Hyperplasia of the intestinal mucosa



Short bowel syndrome



- Disturbed motility
- Bacterial overgrowth
 - *mucosal injury*
 - *bacterial translocation*
- Liver disease

First aim : feed the child

Parenteral nutrition

- Nutritional status
- Avoid gut overload
- Cyclic PN intake
- Complications
- Home

Feeding management

Parenteral nutrition

- Nutritional status
- Avoid gut overload
- Cyclic PN intake
- Complications
- Home

Oral feeding

- Physiological
- EGF from salivary glands
- Self-regulation of intakes
- Digestive secretions
- Prevents eating disorders

Feeding management

Parenteral nutrition

- Nutritional status
- Avoid gut overload
- Cyclic PN intake
- Complications
- Home

Oral feeding

- Physiological
- EGF from salivary glands
- Self-regulation of intakes
- Digestive secretions
- Prevents eating disorders

Continuous enteral tube feeding ?

Feeding management

- Most physiological : oral
- Protein hydrolysate (MCT)
 - consider AA solutions
- Promotion of colon function
- No evidence-based recommendations



Parenteral nutrition : energy

-
- Maximal glucose oxidation rate : 18 g/ kg/d
- Maximal lipid oxidation rate : 3-3.5 g/kg/d
- Inverse relation glucose / lipid oxidation
- Ratio glucose / lipid : 60-75% / 25-40%

Commonly used protein intakes in unstressed children

<i>Age group</i>	<i>Amino acid requirement g.kg⁻¹.d⁻¹</i>	<i>Nitrogen requirement gN kg⁻¹.d⁻¹</i>	<i>Kcal/gN</i>
Very low birth weight infant (<1.5kg)	3.5	0.560	200-250
Term infant	2.0-2.5	0.320-0.400	250
Child	1.5-2.5	0.240-0.400	200-250
Adult	1.0-1.2	0.160-0.190	120-150

IF-associated liver disease

- Limiting factor for bowel adaptation
- Major cause of death

IF-associated liver disease

Patient-related risk factors

- Age and immaturity
- Bowel rest with total PN
- Dysruption of entero-hepatic cycle
 - short bowel, proximal stoma, ileal resection
- Intestinal stasis and bacterial overgrowth
 - motility disorder, no ileocaecal valve
- Infections

Prevention: patient-related factors

- Prevention of catheter-related sepsis
- Prevention of bacterial overgrowth
- Stimulation of digestive function
- Promote oral > continuous tube feeding

Prevention : PN-related factors

- Balanced protein-energy supply
- Use of paediatric amino acid solutions
- Early cyclical parenteral nutrition
- **Use of fish oil-based lipid emulsions**

Fish oil

**EPA (20: 5n-3)
DHAA (22: 6n-3)**

Soybean oil

ARA (20: 4n-6)

Increase inflammation
Decrease antioxidant activity
Increase phytosterols
Decrease bile flow

Decrease inflammation
Increase antioxidant activity
Decrease phytosterols
Increase bile flow

Available lipid emulsions in Europe

	Intralipid	Medialipid	ClinOleic	SMOF	Omegaven
Soybean %	100	50	20	30	0
MCT %	0	50	0	30	0
Olive oil %	0	0	80	25	0
Fish oil %	0	0	0	15	100
Phytosterols mg/l	348±33	200±40	327±8	47.6	0
α-tocopherol mg/l	38	< 30	200	200	150-296
ω-3	+	±	+	++	+++
ω-6	+++	±	+	+	+



Pre- , pro- , and anti-biotics

- !!! Large-spectrum antibiotics
 - microbiota
 - resistances
 - do not change distension / motility
- Trial of metronidazole
- Probiotics : maybe, but which one ?

Surgery in short bowel syndrome

- Dilatation of bowel is normal / adaptation
- Risk of motility disorder / bacterial overgrowth
 - Long dilated segments : tapering
 - Short dilated segments : lengthening
 - Serial transverse enteroplasty (STEP)
 - Longitudinal intestinal lengthening

Lengthening techniques



Outcome after neonatal small bowel resection

- 73% : definitively weaned from PN
- 15% : recurrent nutritional support
- 12% : partial intestinal failure

Hormonal treatment
Non-transplant surgery
Intestinal transplantation ?

Future ?

- Growth hormone and IGF-1
- Glucagon-like peptide 2
- Epidermal growth factor (EGF)
- Tissue engineered intestine
- Transfection of Na/glucose pump
- Parenteral butyrate

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

P B Jeppesen,¹ R Gilroy,² M Pertkiewicz,³ J P Allard,⁴ B Messing,⁵ S J O'Keefe⁶




Reduction of volume of PN

Placebo (n=16)

0.10 mg/kg/day dose (n=32)

0.05 mg/kg/day dose (n=35)

Parenteral volume (ml/day)



Complications of home PN

- Home PN is impossible
- Extensive vascular thrombosis
- Multiple infections
- Progressive IF-associated liver disease
- Growth failure
- Psychological intolerance / HPN

Discussion of transplantation ?

Total AND definitive intestinal failure

AND

complications of home parenteral nutrition

= nutritional failure

Teşekkür ederim bene dilnediniz için !

